AU2001261565A1 - Method for fluoromethylation of alcohols via halogenative decarboxylation - Google Patents
Method for fluoromethylation of alcohols via halogenative decarboxylationInfo
- Publication number
- AU2001261565A1 AU2001261565A1 AU2001261565A AU2001261565A AU2001261565A1 AU 2001261565 A1 AU2001261565 A1 AU 2001261565A1 AU 2001261565 A AU2001261565 A AU 2001261565A AU 2001261565 A AU2001261565 A AU 2001261565A AU 2001261565 A1 AU2001261565 A1 AU 2001261565A1
- Authority
- AU
- Australia
- Prior art keywords
- alpha
- accordance
- group
- formula
- sevoflurane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 49
- 238000005799 fluoromethylation reaction Methods 0.000 title claims description 5
- 238000006114 decarboxylation reaction Methods 0.000 title description 3
- 150000001298 alcohols Chemical class 0.000 title description 2
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims description 31
- 229960002078 sevoflurane Drugs 0.000 claims description 30
- 239000002904 solvent Substances 0.000 claims description 21
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 14
- 239000000460 chlorine Substances 0.000 claims description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 10
- 239000012025 fluorinating agent Substances 0.000 claims description 10
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 239000012320 chlorinating reagent Substances 0.000 claims description 9
- HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical compound ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 claims description 8
- -1 fluoride compound Chemical class 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 8
- PNZVFASWDSMJER-UHFFFAOYSA-N acetic acid;lead Chemical compound [Pb].CC(O)=O PNZVFASWDSMJER-UHFFFAOYSA-N 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical group CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 230000000911 decarboxylating effect Effects 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 13
- 239000003193 general anesthetic agent Substances 0.000 description 8
- 229940035674 anesthetics Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 150000002170 ethers Chemical class 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- BLIQUJLAJXRXSG-UHFFFAOYSA-N 1-benzyl-3-(trifluoromethyl)pyrrolidin-1-ium-3-carboxylate Chemical compound C1C(C(=O)O)(C(F)(F)F)CCN1CC1=CC=CC=C1 BLIQUJLAJXRXSG-UHFFFAOYSA-N 0.000 description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- FQFKTKUFHWNTBN-UHFFFAOYSA-N trifluoro-$l^{3}-bromane Chemical compound FBr(F)F FQFKTKUFHWNTBN-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 239000011698 potassium fluoride Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000003682 fluorination reaction Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CXJWJJZGJZNBRK-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoro-2-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)propane Chemical class FC(F)(F)C(C(F)(F)F)OC(C(F)(F)F)C(F)(F)F CXJWJJZGJZNBRK-UHFFFAOYSA-N 0.000 description 2
- HHYFUCXZHKDNPT-UHFFFAOYSA-N 2-(chloromethoxy)-1,1,1,3,3,3-hexafluoropropane Chemical compound FC(F)(F)C(C(F)(F)F)OCCl HHYFUCXZHKDNPT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910001512 metal fluoride Inorganic materials 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NSGXIBWMJZWTPY-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropane Chemical class FC(F)(F)CC(F)(F)F NSGXIBWMJZWTPY-UHFFFAOYSA-N 0.000 description 1
- YRNYDOLJFCUCNM-UHFFFAOYSA-N 2-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)acetic acid Chemical compound OC(=O)COC(C(F)(F)F)C(F)(F)F YRNYDOLJFCUCNM-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 206010021089 Hyporeflexia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- DLEGDLSLRSOURQ-UHFFFAOYSA-N fluroxene Chemical compound FC(F)(F)COC=C DLEGDLSLRSOURQ-UHFFFAOYSA-N 0.000 description 1
- 229950010045 fluroxene Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical group OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
Description
METHOD FOR FLUOROMETHYLATION OF ALCOHOLS VIA HALOGENATIVE DECARBOXYLATION
Field of the Invention
The present invention is directed to a method for fluoromethylation of an alcohol. In particular, the present invention is directed to a method in which an alcohol is reacted with an alpha-haloester to form an alpha-alkoxy acid which is then decarboxylatively halogenated to form a chloromethyl ether. The chloromethyl ether is then converted to the desired fluoride by reacting it with a fluorinating agent.
Background of the Invention
Anesthetics belong to a class of biochemical depressant drugs which affect the vital functions of cells. Anesthetics generally produce analgesia, loss of consciousness, diminished reflex activity, and muscular relaxation, with minimal depression of the vital functions. Anesthetics may be gaseous (volatile) or fixed (non-volatile). Gaseous anesthetics are inhaled and enter the bloodstream through the lungs while fixed anesthetics are administrated parenterally or through the alimentary canal.
Many currently used gaseous anesthetics are halogenated compounds. These compounds tend to cause less metabolic disturbance and are less flammable than traditional gaseous anesthetic compounds such as ether and cyclopropane. Examples of halogenated anesthetic compounds include halothane (CF3CHBrCl) and trichloroethylene (Cl2C=CHCl)as well as halogenated ether compounds such as enflurane (CHF2OCF2CHClF), fluroxene (CF3CH2OCH=CH2), methoxyflurane (Cl2CHCF2OCH3),and isoflurane (CF3CHClOCHF2).
A particularly useful halogenated ether anesthetic is sevoflurane, (CF3)2CHOCH2F, also known as 2-(fluoromethoxy)- 1,1,1,3,3,3,-hexafluoropropane or fluoromethyl- l,l,l,3.3,3-hexafluoro-2-propyl ether. Sevoflurane is today one of the most important and
widely used general anesthetics. Sevoflurane combines various characteristics that are most desirable in an inhalation anesthetic, including the lowest blood/gas partition coefficient of 0.63, smooth induction and recovery from anesthesia, minimal irritation to the upper respiratory tract, low metabolic rate, and rapid elimination. In addition, sevoflurane is suitable for out-patient surgery use. Although sevoflurane's definitive mechanism of action has not been elucidated, it has recently been shown that sevoflurane interacts with nicotinic acetylcholine receptors by affecting the open and closed state of the ion channels at clinical and lower concentrations. Sevoflurane may also effect reversible modulation of GABA and glycine receptors. The above suggest that at least part of the anesthetic action of sevoflurane may be due to interactions between sevoflurane and specific voltage-gated ion channels.
The preparation of fluorinated compounds such as sevoflurane tends to be difficult because of the limited number of selective fluorination reactions available. Direct fluorination of organic compounds to replace hydrogen is statistical, non-selective, and generally accompanied by the formation of many side products. Hence, fluorinated compounds are usually prepared by first synthesizing a substituted organic intermediate, wherein the substituent group is at the site to be fluorinated, and then displacing the substituent group with a fluoride ion. Metal fluorides, for example, have been used to displace chlorine substituent groups.
Several synthetic routes to sevoflurane employ hexafluoroisopropyl alcohol (HFIP) as a starting material. For example, U.S. Patent No. 3,683,092 discloses a method for synthesizing sevoflurane involving the methylation of hexafluoroisopropyl alcohol followed by fluorination with either (a) bromine trifluoride, or (b) chlorine gas, followed by potassium fluoride. U.S. Patent No. 4,469,898 discloses a method for synthesizing sevoflurane which includes the mixing of hexafluoroisopropyl alcohol, formaldehyde, hydrogen fluoride, and a protonating, dehydrating and fluoride ion generating agent. U.S. Patent No. 4,250,334 discloses a method for synthesizing sevoflurane by adding HFIP to a mixture of a stoichiometric excess of paraformaldehyde and hydrogen fluoride, plus sufficient sulfuric acid to sequester most of the water produced by the reaction. U.S. Patent No. 4,314,087 discloses a method for synthesizing sevoflurane by reacting HFIP with hydrogen fluoride and a formaldehyde.
The routes disclosed in the referenced patents can result in unwanted by-products.
which may be difficult to separate from sevoflurane produced by the synthesis. Moreover, the use of corrosive materials in these synthetic routes requires specialized equipment and special handling precautions.
Other methods used to make hexafluoroisopropyl ethers include the conversion of 1,1,1,3,3,3-hexachloroisopropyl ethers to 1,1,1,3,3,3-hexafluoroisopropyl ethers. For example, methyl 1,1,1,3,3,3-hexachloroisopropyl ether and chloromethyl 1,1,1,3,3,3- hexachloroisopropyl ether can be converted to sevoflurane by reaction of each of the above compounds with bromine trifluoride. Hexafluoroisopropyl ethers also can be made by reacting each of these chlorinated compounds with hydrogen fluoride, followed by reaction with bromine trifluoride. U.S. Patent No. 4,874,901 discloses a method for fluorinating halogenated ether compounds, wherein compounds such as sevoflurane can be prepared by reacting chloromethyl hexafluoroisopropyl ether with either potassium fluoride or sodium fluoride. However, the chlorine replacement methods are not desirable because large volumes of chloride are released in the synthetic process, the yields are low, and multiple chloro-fluoro intermediates are formed. The intermediates must be removed to obtain the final ether product, sevoflurane. The purification processes increase the difficulty and cost of synthesis of 1,1, 1,3,3, 3 -hexafluoroisopropyl ethers by these methods.
Hexafluoropropanes alternatively have been synthesized from malononitrile in the presence of bromine trifluoride, as disclosed in U.S. Patent Nos. 5,789,630 and 5,705,710.
Another potential route to sevoflurane is by fluorodecarboxylation. Patrick et al.,J. Org. Chem. 48, 4158-4159 (1983), reports that alkyl carboxylic acids can undergo fluorodecarboxylation with xenon difluoride (XeF2) in the presence of hydrogen fluoride. Although the use of xenon difluoride on a small scale can be effective, the cost of xenon difluoride makes its use impractical on a large scale. Furthermore, when alkoxyacetic acids are fluorodecarboxylated with xenon difluoride, significant amounts of side products are formed. Replacement of a carboxylic acid group with a fluorine group has also been disclosed in U.S. Patent No. 4,996,371 and in RE 35,568 which teach a reaction of hydrogenated aliphatic carboxylic acid compounds with bromine trifluoride; and in U.S. Patent No. 4,847,427, which teaches a method for preparing fluorocarbon polyethers by neutralizing a perfluorinated carboxylic acid by heating with fluorine in the presence of metal fluoride to replace the carboxylic acid group.
While the above-discussed methods are useful for preparing certain fluorinated compounds, these methods can be complex, expensive, and often provide fluorinated products in low yield together with considerable amounts of side products. Hence there is a need for improved procedures for the preparation of fluorinated compounds.
The present invention provides an improved procedure for the preparation of fluorinated compounds, including sevoflurane and other fluorinated anesthetics.
It is an object of the present invention to provide a method for the preparation of fluorine-containing organic compounds. Still a further object is to provide a method whereby a fluorine-containing organic compound may be prepared from a partially chlorinated, brominated, or iodinated organic compound. An additional object is to provide a method for preparing a fluorine containing organic compound whereby the formation of undesirable decomposition or side products is substantially avoided.
Summary of the Invention
The invention is directed to a novel method for fluoromethylation of an alcohol via halogenative decarboxylation. The method includes the steps of:
(a) reacting an alcohol of the formula R1C(CX3)2OH with an alpha- haloester of the formula X2CH2CO2R2 under basic conditions in the presence of a first solvent to form an alpha-alkoxyester, wherein R1 is either hydrogen or an alkyl group, wherein R2 is either hydrogen or an alkyl group, wherein X, at each occurrence, is independently selected from the group consisting of hydrogen, chlorine, bromine, or fluorine, and wherein X2 is selected from the group consisting of bromine and chlorine;
(b) saponifying the alpha alkoxyester to form an alpha-alkoxy acid;
(c) refluxing the alpha-alkoxy acid with lead tetraacetate and a chlorinating agent in the presence of a second solvent to form a chloride compound of the formula R1C(CX3)2OCH2Cl; and
(d) converting the chloride compound to a fluoride compound of the formula R1C(CX3)2OCH2F with a fluorinating agent in the presence of a third solvent. In another aspect, the invention is directed to a method for synthesizing sevoflurane
by:
(a) reacting 1,1,1,3,3,3-hexafiuoroisopropanol with an alpha-haloester of the formula X2CH2CO2R2 under basic conditions in a first solvent to form an alpha- alkoxy ester, wherein R2 is either hydrogen or an alkyl group, and wherein X2 is selected from the group consisting of bromine and chlorine;
(b) saponifying the alpha-alkoxy ester to a carboxylic acid;
(c) halogenatively decarboxylating the carboxylic acid with lead tetraacetate and a chlorinating agent in a second solvent to form sevochlorane; and
(d) converting sevochlorane to sevoflurane with a fluorinating agent in the presence of a third solvent.
Brief Description of the Drawings
FIG. 1 depicts an embodiment of the reaction of the present invention.
Detailed Description of the Invention
As used herein, the term "alkyl" means straight or branched, saturated or unsaturated carbon chains having up to 10, preferably up to 6 and more preferably up to 4 carbon atoms. This term is also meant to encompass alkenyl and alkynyl groups.
As used herein, "hexafluoroisopropanol" and "HFIP" mean 1,1,1,3,3,3- hexafluoroisopropyl alcohol. As used herein, "sevochlorane" means a compound of the formula (CF3)2CHOCH2Cl.
In accordance with the method of the present invention, an alcohol of the general formula R1C(CX3)2OH, e.g., hexafluoroisopropanol, is reacted with ahalide of the general formula X2CH2CO2R2 , e.g., ethyl bromoacetate, under basic conditions in the presence of a first solvent to form an alpha-alkoxy ester. In this reaction, R1 is hydrogen or an alkyl group, and R2 is hydrogen or an alkyl group. In a preferred embodiment, R2 is an alkyl group. X, at each occurrence, is independently selected from the group consisting of hydrogen, bromine, fluorine, and chlorine. X2 is selected from the group consisting of bromine and chlorine. The resulting alpha-alkoxy ester is then saponified to form an alpha-alkoxy acid. For example,
saponification of the alpha-alkoxy ester preferably is achieved by heating with aqueous LiOH. The alpha-alkoxy acid is then heated at reflux with lead tetraacetate and a chlorinating agent, e.g., lithium chloride, in the presence of a second solvent, e.g., benzene, to form a chloromethyl ether of the formula R1C(CX3)2OCH2Cl. Finally, the chloromethyl ether is converted to a fluoride compound of the formula R1C(CX3)2OCH2F by reacting it with a fluorinating agent in the presence of a third solvent.
In another aspect, the present invention is directed to a method for synthesizing sevoflurane from HFIP, as set forth in FIG. 1. In this reaction, hexafluoroisopropanol is reacted with an alpha-haloester of the formula X2CH2CO2R2 under basic conditions in the presence of a first solvent to form an alpha-alkoxy ester. In this reaction, R2 is an alkyl group and X2 is selected from the group consisting of bromine and chlorine. The resulting ester is then saponified to a carboxylic acid which is then halogenatively decarboxylated with lead tetraacetate and a chlorinating agent in the presence of a second solvent to form sevochlorane. The resulting sevochlorane is then reacted with a fluorinating agent in the presence of a third solvent to form sevoflurane.
One of ordinary skill will appreciate that a variety of known fluorinating agents can be used in connection with the methods of the present invention. For example, KF can be used to fluorinate the chloromethyl ether compounds in accordance with the methods of the present invention.
One of ordinary skill also will appreciate that a variety of known chlorinating agents can be used in comiection with the methods of the present invention. For example, lithium chloride or sodium chloride can be used in accordance with the method of the present invention.
As above-indicated, ethyl bromoacetate can be used in accordance with the method of the present invention. However, one of ordinary skill in the art will appreciate that other alpha-haloesters can be used efficaciously in accordance with the reactions of the present invention. For example, methyl bromoacetate may also be utilized as an alpha-haloester in connection with the reactions of the present invention.
Suitable first solvents include tetrahydrofuran (THF) and diethyl ether.
Suitable second solvents include aromatic solvents such as benzene. Other appropriate second solvents include 1,4-dioxane.
The third solvent may have the formula HO-(CH2CH2O)nH wherein n is an integer from one to twenty, and preferably n is an integer of from eight to ten. A presently preferred third solvent is PEG400, i.e., a polyethylene glycol having an average molecular weight of 400.
The basic conditions of the method can be obtained by a variety of suitable methods known to those skilled in the art. For example, NaH can be added to the reaction mixture.
Saponification of the alpha alkoxycarboxy anion in accordance with the reaction of the present invention may be performed by a variety of suitable methods known to those skilled in the art. For example, the substrate can be saponified by heating with aqueous LiOH.
The following examples are presented for illustrative purposes only, and are not intended to limit the scope of the invention, which is as defined in the claims below. All analyses were conducted by gas chromatography. All percentages are by mole percent.
Example 1
Alpha-(hexafluoroisopropoxy)acetic acid was synthesized in the following manner as shown in Reaction Scheme I.
Reaction Scheme I
Into a flame-dried 250 mL round-bottomed flask was placed dry sodium hydride (2.4 g, 100 mmol) and 100 mL of anhydrous tetrahydrofuran. The resultant slurry was maintained under a nitrogen atmosphere while cooling to 0° C in an ice bath. To this slurry was added 1,1,1,3,3,3-hexafluoroisopropanol (11.6 mL, 110 mmol) dropwise while stirring. The pre-formed alkoxide was stirred for an additional 15 minutes before adding ethyl
bromoacetate (11.1 mL, 100 mmol) in a single portion. The mixture was allowed to warm gradually to ambient temperature while stirring overnight. The reaction mixture was filtered and concentrated in vacuo. The resultant crude ester was heated for two hours at reflux in water (100 mL) with an equivalent of LiOH (4.2 g, 100 mmol) added. The reaction mixture was cooled and IN aqueous KOH solution added, bringing the pH to >13. The basic solution was extracted with ether (2 x 75mL) and then acidified to pH 1 with concentrated HC1. The product was extracted with CH2C12 (3 x 75mL), dried over Na2SO4, filtered, and concentrated in vacuo to afford 15.0g (66%) of the a-alkoxy acid as a white solid.
Example 2
Sevochlorane was synthesized via decarboxylative halogenation (according to the procedure of Kochi, J.K. J. Am. Chem. Soc. 1965, 87, 1811) as follows, as shown in Reaction Scheme II.
Reaction Scheme II
Scheme II To a solution of a-(hexafluoroisopropoxy)acetic acid (4.90 g, 21.7 mmol) dissolved in anhydrous benzene (43 mL) was added lead tetraacetate (10.11 g, 21.7 mmol) and then lithium chloride (919 mg, 21.7 mmol), and the mixture was sparged with dry nitrogen for 10 minutes. The degassed reaction mixture was heated at reflux for 20 minutes until the initial cloudy yellow slurry had become a clear solution with a gummy white precipitate, and gas evolution had ceased. GC/MS analysis of the crude reaction mixture showed sevochlorane to be the major product along with a small amount of methyl chloride and minor impurities. The product was distilled directly from the reaction mixture at a temperature of 77-78° C as a
co-distillate with benzene. The product solution was used directly in the subsequent conversion to sevoflurane.
Example 3
Sevoflurane was synthesized in the following manner, as shown in Reaction Scheme III.
Reaction Scheme III
The sevochlorane/benzene distillate from the previous procedure (Example 2) was combined with PEG-400 (43 mL) and 5 equivalents of KF (6.3 g, 0.11 mol) and heated at 100-110 °C for two hours. The product was distilled directly from the reaction flask to afford 1.2 g (28% for two steps) of sevoflurane.
All references cited are hereby incorporated by reference.
The present invention is illustrated by way of the foregoing description and examples. The foregoing description is intended as a non-limiting illustration, since many variations will become apparent to those skilled in the art in view thereof. It is intended that all such variations within the scope and spirit of the appended claims be embraced thereby.
Changes can be made in the composition, operation and arrangement of the method of the present invention described herein without departing from the concept and scope of the invention as defined in the following claims:
Claims (12)
1. A method for fluoromethylation of an alcohol comprising the steps of: reacting an alcohol of the formula R1C(CX3)2OH with an alpha-haloester of the formula X2CH2CO2R2 to form an alpha-alkoxy ester, wherein R1 is selected from the group consisting of hydrogen and alkyl groups, wherein R2 is selected from the group consisting of hydrogen and alkyl groups, wherein X, at each occurrence, is independently selected from the group consisting of hydrogen, bromine, fluorine, and chlorine, and wherein X2 is selected from the group consisting of bromine and chlorine; saponifying said alpha-alkoxy ester to form an alpha-alkoxy acid; heating at reflux said alpha-alkoxy acid with lead tetraacetate and a chlorinating agent to form a chloromethyl ether of the formula R!C(CX3)2OCH2Cl; and converting said chloromethyl ether to a fluoride compound of the formula R1C(CX3)2OCH2F with a fluorinating agent.
A method in accordance with Claim 1 , wherein said fluorinating agent is KF.
3. A method in accordance with Claim 1, wherein said chlorinating agent is lithium chloride.
4. A method in accordance with Claim 1, wherein said step of reacting an alcohol with an alpha-haloester is conducted under basic conditions.
5. A method in accordance with Claim 1, wherein said step of reacting an alcohol with an alpha-haloester is conducted in the presence of an ether solvent.
6. A method in accordance with Claim 1, wherein said step of heating at reflux is conducted in the presence of a second solvent selected from the group consisting of benzene and dioxane.
7. A method in accordance with Claim 1, wherein said step of converting said chloromethyl ether to a fluoride compound is conducted in the presence of a third solvent.
8. A method in accordance with Claim 7, wherein said third solvent has a formula HO-(CH2CH2O)nH wherein n is an integer from one to twenty.
9. A method for synthesizing sevoflurane comprising the steps of: reacting 1,1,1,3,3,3-hexafluoroisopropanol with an alpha-haloester of the formula X2CH2CO2R2 to form an alpha-alkoxy ester, wherein R2 is an alkyl group, and wherein X2 is selected from the group consisting of bromine and chlorine; saponifying said ester to a carboxylic acid; halogenatively decarboxylating said carboxylic acid with lead tetraacetate and a chlorinating agent to form sevochlorane; and converting sevochlorane to sevoflurane with a fluorinating agent.
10. A method in accordance with Claim 9, wherein said alpha-haloester is ethyl bromoacetate.
11. A method in accordance with Claim 9, wherein said fluorinating agent is KF.
12. A method in accordance with Claim 9, wherein said chlorinating agent is lithium chloride.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/587,417 US6271422B1 (en) | 2000-06-01 | 2000-06-01 | Method for fluoromethylation of alcohols via halogenative decarboxylation |
| US09/587,417 | 2000-06-01 | ||
| PCT/US2001/015516 WO2001094286A1 (en) | 2000-06-01 | 2001-05-14 | Method for fluoromethylation of alcohols via halogenative decarboxylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001261565A1 true AU2001261565A1 (en) | 2002-03-07 |
| AU2001261565B2 AU2001261565B2 (en) | 2006-07-20 |
Family
ID=24349720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU6156501A Pending AU6156501A (en) | 2000-06-01 | 2001-05-14 | Method for fluoromethylation of alcohols via halogenative decarboxylation |
| AU2001261565A Ceased AU2001261565B2 (en) | 2000-06-01 | 2001-05-14 | Method for fluoromethylation of alcohols via halogenative decarboxylation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU6156501A Pending AU6156501A (en) | 2000-06-01 | 2001-05-14 | Method for fluoromethylation of alcohols via halogenative decarboxylation |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6271422B1 (en) |
| EP (1) | EP1286939B1 (en) |
| JP (1) | JP2004508293A (en) |
| KR (1) | KR100799895B1 (en) |
| CN (1) | CN1283606C (en) |
| AR (1) | AR028664A1 (en) |
| AT (1) | ATE317839T1 (en) |
| AU (2) | AU6156501A (en) |
| BG (1) | BG107336A (en) |
| BR (1) | BR0110776A (en) |
| CA (1) | CA2410428A1 (en) |
| CZ (1) | CZ20023790A3 (en) |
| DE (1) | DE60117258T2 (en) |
| DK (1) | DK1286939T3 (en) |
| ES (1) | ES2258085T3 (en) |
| HK (1) | HK1054371B (en) |
| HU (1) | HUP0302239A3 (en) |
| IL (2) | IL152857A0 (en) |
| MX (1) | MXPA02011851A (en) |
| NO (1) | NO20025791L (en) |
| NZ (1) | NZ522502A (en) |
| PE (1) | PE20011339A1 (en) |
| PL (1) | PL364001A1 (en) |
| PT (1) | PT1286939E (en) |
| SK (1) | SK17512002A3 (en) |
| TW (1) | TWI222435B (en) |
| UY (1) | UY26738A1 (en) |
| WO (1) | WO2001094286A1 (en) |
| ZA (1) | ZA200208850B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083580B2 (en) | 2001-04-06 | 2006-08-01 | Mattioli Engineering Ltd. | Method and apparatus for skin absorption enhancement and transdermal drug delivery |
| ATE365034T1 (en) * | 2003-09-10 | 2007-07-15 | Cristalia Prod Quimicos Farm | STABLE PHARMACEUTICAL COMPOSITION OF A FLUORETHER COMPOUND FOR ANESTHESIA, METHOD FOR STABILIZING A FLUORETHER COMPOUND, USE OF A STABILIZING AGENT TO EXCLUDE THE DEGRADATION OF A FLUORETHER COMPOUND |
| WO2006055748A2 (en) * | 2004-11-17 | 2006-05-26 | Minrad Inc. | Method for the preparation of sevoflurane |
| CN103664584B (en) * | 2013-12-23 | 2015-06-03 | 湖南方盛制药股份有限公司 | Method for preparing a-fluoro-propionyl acetate |
| CN104529721B (en) * | 2015-01-16 | 2017-04-19 | 河北一品制药有限公司 | Industrial preparation method of sevoflurane |
| CN107698430B (en) * | 2017-11-01 | 2021-01-08 | 华东医药(西安)博华制药有限公司 | Post-treatment method of sevoflurane reaction liquid |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1250928A (en) * | 1968-10-28 | 1971-10-27 | ||
| US3683092A (en) | 1970-07-31 | 1972-08-08 | Baxter Laboratories Inc | Method of anesthesia |
| US4314087A (en) | 1979-12-26 | 1982-02-02 | Baxter Travenol Laboratories, Inc. | Methods of synthesizing hexafluoroisopropanol from impure mixtures and synthesis of a fluoromethyl ether therefrom |
| US4250334A (en) | 1979-12-26 | 1981-02-10 | Baxter Travenol Laboratories, Inc. | Method of synthesizing fluoromethylhexafluoroisopropyl ether |
| US4469898A (en) | 1979-12-26 | 1984-09-04 | Baxter Travenol Laboratories, Inc. | Method of synthesizing fluoromethylhexafluoroisopropyl ether |
| JPS57209235A (en) * | 1981-06-18 | 1982-12-22 | Sumitomo Chem Co Ltd | Tetrahydronaphthalene derivative and its preparation |
| US4847427A (en) | 1988-04-13 | 1989-07-11 | E. I. Du Pont De Nemours And Company | Process for preparing fluorocarbon polyethers |
| US4874901A (en) * | 1988-05-06 | 1989-10-17 | Boc, Inc. | Process for the production of polyfluorinated ethers |
| US4996371A (en) | 1990-01-16 | 1991-02-26 | Boc, Inc. | Method for fluorodecarboxylation |
| EP0822172B2 (en) * | 1996-02-21 | 2004-10-06 | Central Glass Company, Limited | Process for preparing fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether |
| US5789630A (en) | 1996-02-27 | 1998-08-04 | University Of Iowa Research Foundation | Process for the synthesis of hexafluoropropanes |
| US5705710A (en) | 1997-01-15 | 1998-01-06 | University Of Iowa Research Foundation | Process for the synthesis of hexafluoroisopropyl ethers |
| US5969193A (en) * | 1997-08-18 | 1999-10-19 | Medeva Pharmaceuticals Pa, Inc. | Method for the preparation of sevoflurane |
| US5886239A (en) * | 1997-11-21 | 1999-03-23 | Baxter International Inc. | Method of preparing monofluoromethyl ethers |
| US6100434A (en) * | 1999-03-26 | 2000-08-08 | Abbott Laboratories | Method for synthesizing sevoflurane and an intermediate thereof |
| US6303831B1 (en) * | 2000-06-01 | 2001-10-16 | Abbott Laboratories | Synthetic method for fluoromethylation of halogenated alcohols |
| US6245949B1 (en) * | 2000-06-01 | 2001-06-12 | Abbott Laboratories | Synthetic method for the fluoromethylation of alcohols |
-
2000
- 2000-06-01 US US09/587,417 patent/US6271422B1/en not_active Expired - Lifetime
-
2001
- 2001-05-14 DK DK01935471T patent/DK1286939T3/en active
- 2001-05-14 PT PT01935471T patent/PT1286939E/en unknown
- 2001-05-14 CZ CZ20023790A patent/CZ20023790A3/en unknown
- 2001-05-14 AU AU6156501A patent/AU6156501A/en active Pending
- 2001-05-14 BR BR0110776-3A patent/BR0110776A/en not_active IP Right Cessation
- 2001-05-14 EP EP01935471A patent/EP1286939B1/en not_active Expired - Lifetime
- 2001-05-14 HK HK03105010.2A patent/HK1054371B/en not_active IP Right Cessation
- 2001-05-14 ES ES01935471T patent/ES2258085T3/en not_active Expired - Lifetime
- 2001-05-14 CN CNB018104053A patent/CN1283606C/en not_active Expired - Fee Related
- 2001-05-14 JP JP2002501804A patent/JP2004508293A/en not_active Ceased
- 2001-05-14 CA CA002410428A patent/CA2410428A1/en not_active Abandoned
- 2001-05-14 PL PL01364001A patent/PL364001A1/en not_active IP Right Cessation
- 2001-05-14 NZ NZ522502A patent/NZ522502A/en unknown
- 2001-05-14 IL IL15285701A patent/IL152857A0/en unknown
- 2001-05-14 AU AU2001261565A patent/AU2001261565B2/en not_active Ceased
- 2001-05-14 DE DE60117258T patent/DE60117258T2/en not_active Expired - Fee Related
- 2001-05-14 WO PCT/US2001/015516 patent/WO2001094286A1/en not_active Ceased
- 2001-05-14 MX MXPA02011851A patent/MXPA02011851A/en active IP Right Grant
- 2001-05-14 HU HU0302239A patent/HUP0302239A3/en unknown
- 2001-05-14 KR KR1020027016188A patent/KR100799895B1/en not_active Expired - Fee Related
- 2001-05-14 AT AT01935471T patent/ATE317839T1/en not_active IP Right Cessation
- 2001-05-14 SK SK1751-2002A patent/SK17512002A3/en unknown
- 2001-05-31 UY UY26738A patent/UY26738A1/en not_active Application Discontinuation
- 2001-05-31 AR ARP010102630A patent/AR028664A1/en unknown
- 2001-06-01 PE PE2001000507A patent/PE20011339A1/en not_active Application Discontinuation
- 2001-06-01 TW TW090113351A patent/TWI222435B/en not_active IP Right Cessation
-
2002
- 2002-10-31 ZA ZA200208850A patent/ZA200208850B/en unknown
- 2002-11-14 IL IL152857A patent/IL152857A/en not_active IP Right Cessation
- 2002-11-28 BG BG107336A patent/BG107336A/en unknown
- 2002-12-02 NO NO20025791A patent/NO20025791L/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1286939B1 (en) | Method for fluoromethylation of alcohols via halogenative decarboxylation | |
| AU2001261565A1 (en) | Method for fluoromethylation of alcohols via halogenative decarboxylation | |
| US6245949B1 (en) | Synthetic method for the fluoromethylation of alcohols | |
| AU2001265158A1 (en) | Synthetic method for the fluoromethylation of alcohols | |
| US6303831B1 (en) | Synthetic method for fluoromethylation of halogenated alcohols | |
| AU2001265129A1 (en) | Synthetic method for fluoromethylation of halogenated alcohols |